Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRNP | P04156 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HBB | P68871 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL204774 | 0.81 | F7 (0.34) | GRIN2BMAPTTP53HBBSMN1; SMN2 | |
| SCHEMBL409582 | 0.68 | MAPT (0.65) | PRNPGRIN2BMAPTTP53HBB | |
| SCHEMBL9942538 | 0.68 | CNR1 (0.36) | MAPTSMN1; SMN2 | |
| SCHEMBL15885534 | 0.62 | TP53 (0.36) | GRIN2BMAPTTP53HBBSMN1; SMN2 | |
| SCHEMBL24306161 | 0.60 | CNR2 (0.38) | GRIN2BMAPT | |
| SCHEMBL3032129 | 0.58 | NPC1 (0.60) | MAPTTP53SMN1; SMN2 | |
| SCHEMBL13379899 | 0.58 | NPC1 (0.65) | MAPTTP53SMN1; SMN2 | |
| SCHEMBL29141445 | 0.57 | TLR8 (0.36) | PRNP | |
| SCHEMBL16731006 | 0.56 | ENPP2 (0.54) | PRNPMAPT | |
| SCHEMBL12727901 | 0.55 | TSHR (0.47) | MAPTTP53HBBSMN1; SMN2DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283475-B2 | Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof | MERIAL LIMITED (US) | 2012-10-09 | — | — | US | disclosed |
| US-20120149750-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL, INC. | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149750-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | CYP4X1, CBR3, TYR | PRNP 2922/4885GRIN2B 2296/4885MAPT 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.